p120 regulates E-cadherin expression in nasal epithelial cells in chronic rhinosinusitis.

BACKGROUND: The epithelial barrier plays an important role in the regulation of immune homeostasis. The effect of the immune environment on E-cadherin has been demonstrated in previous studies. This discovery prompted new research on the targeting mechanism of E-cadherin in chronic rhinosinusitis (CRS). METHODS: E-cadherin and p120 expression was determined by quantitative RT-PCR, and western blot. The interaction between E-cadherin and p120 was assessed by immunofluorescence staining and coimmunoprecipitation assays. Human nasal epithelial cells (HNECs) were cultured with submerged methods and transfected with p120-specific small interfering RNA. In other experiments, HNECs differentiated with the air-liquid interface (ALI) method were stimulated with various cytokines and Toll-like receptor (TLR) agonists. The barrier properties of differentiated HNECs were determined by assessing fluorescent dextran permeability. RESULTS: E-cadherin and p120 expression was decreased in HNECs from patients with CRS, and the p120 protein expression level was positively correlated with that of E-cadherin. Two isoforms of p120 (p120-1 and p120-3) were expressed in HNECs, with p120-3 being the main isoform. Knocking down p120 in HNECs cultured under submerged conditions significantly reduced the E-cadherin protein expression. The Rac1 inhibitor NSC23766 reversed the protein expression of E-cadherin in p120 knockdown experiments. Inflammatory mediators, including IL-4, TNF-α, TGF- ß, LPS and IFN-Î, reduced E-cadherin and p120 protein expression and increased paracellular permeability. Dexamethasone abolished the downregulation of E-cadherin and p120 caused by inflammatory mediators. CONCLUSIONS: p120 is involved in regulating E-cadherin protein expression in CRS. Dexamethasone may alleviate the reduction in E-cadherin and p120 protein expression caused by inflammatory mediators.

[Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19].

To investigate the early changes of peripheral blood leukocyte differential counts in patients with COVID-19. Ten patients with COVID-19 and 30 patients with other viral pneumonia (non-COVID-19) admitted to The Sixth People's Hospital of Shanghai and Jinshan Branch Hospital from January 22 to February 17, 2020 were enrolled in this study. The differential counts of white blood cells (WBC) were analyzed. Patients in COVID-19 group showed relatively lower absolute WBC count 4.95(3.90,6.03)×10(9)/L, lymphocyte absolute count 1.20(0.98,1.50)×10(9)/L and eosinophil absolute count 0.01(0.01,0.01)×10(9)/L. Leukopenia developed in two patients(2/10), lymphocytopenia also in two patients(2/10). Seven over ten patients presented with eosinophil cytopenia. In non-COVID-19 group, absolute WBC count was 8.20(6.78,9.03)×10(9)/L (P<0.001), lymphocyte absolute count 1.75(1.20,2.53)×10(9)/L(P=0.036), eosinophil absolute count 0.02(0.01,0.03)×10(9)/L(P=0.005). Lymphocytopenia occurred in 16.7% patients, eosinophil cytopenia in 16.7% patients too. In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non-COVID-19 patients.

[Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19].

To investigate the early changes of peripheral blood leukocyte differential counts in patients with COVID-19. Ten patients with COVID-19 and 30 patients with other viral pneumonia (non-COVID-19) admitted to Shanghai Jiao Tong University Affiliated Sixth People's Hospital and Jinshan Branch Hospital from January 22 to February 17, 2020 were enrolled in this study. The differential counts of white blood cells were analyzed. Patients in COVID-19 group showed relatively lower absolute white blood cell (WBC) count 4.95(3.90,6.03)×10(9)/L, lymphocyte absolute count 1.20(0.98,1.50)×10(9)/L and eosinophil absolute count 0.01(0.01,0.01)×10(9)/L. Leukopenia developed in two patients(2/10), lymphocytopenia also in two patients(2/10). Seven over ten patients presented with eosinophil cytopenia. In non-COVID-19 group, absolute WBC count was 8.20 (6.78,9.03) ×10(9)/L (P<0.001), lymphocyte absolute count 1.75(1.20,2.53)×10(9)/L(P=0.036), eosinophil absolute count 0.02(0.01,0.03)×10(9)/L(P=0.05). Lymphocytopenia occurred in (16.7%) patients, eosinophil cytopenia in 16.7% patients too. In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients.

[Clinical analysis of 17 cases of anti-neutrophil cytoplasmic antibody associated vasculitis combined with chronic rhinosinusitis].

Objective: To analyse the clinical characteristics of patients of anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) combined with chronic rhinosinusitis (CRS) and its diagnostic strategy. Methods: A retrospective analysis of 228 patients with AAV treated in Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology from August 2008 to June 2018 was performed. Among them, 17 (7.5%, 17/228) patients(10 males and 7 females, with the range of age from 17 to 67 years old) had CRS and their clinical manifestations, laboratory examinations, treatment and prognosis were summarized and studied. Results: In addition to nasal obstruction and increased nasal secretion, 17 AAV patients with CRS were accompanied by cough, wheezing and other pulmonary symptoms (5/17), fever (7/17) and anemia (7/17). Laboratoy tests showed positive ANCA (14/17), increased C-reactive protein (9/17), haematuria (8/17) and proteinuria (6/17). Except for 2 patients who went to other hospital, most patients (14/15) were relieved by glucocorticoid and immunosuppressive therapy. Conclusions: AAV patients with CRS may be accompanied by systemic and pulmonary symptoms (cough, asthma, fever, anemia, etc) or some positive laboratory tests (elevated C-reactive protein, proteinuria and/or hematuria, etc.). To achieve the goal of early diagnosis of AAV, ANCA test and biopsy are recommended for those patients with AAV and CRS concurrently.

Study of autoantibodies against the adenine nucleotide translocator in idiopathic dilated cardiomyopathy.

The frequency, dynamical change and effects of autoantibodies against the adenine nucleotide translocator (ANT) in idiopathic dilated cardiomyopathy (IDC) were studied. Sera of 16 patients with IDC showed significant binding capacity to the ANT protein (33.3%). Anti-ANT antibody titre was gradually tapered in approx. 2-3 months duration. However, anti-ANT antibody can inhibit the ADP/ATP exchange of heart mitochondria and be organ-specific. Short-term (6 weeks) treatment of 15 anti-ANT antibody-positive IDC patients with prednisone was of beneficial effect. Our results show that autoimmunity to the ANT can contribute to the pathogenesis and/or progression of IDC to a certain extent. But we must pay more attention to the fact that anti-ANT antibody characteristically exists short-term. Therefore, a short-term immunosuppressive treatment should be given to those IDC patients whose anti-ANT antibody is positive.